Spasticity – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Spasticity is a stretch reflex disorder clinically manifested as an increase in muscle tone that becomes more noticeable with faster-stretching movements. Upper motor neuron syndrome is typical of lesions that damage upper motor neurons (UMNS). The exaggeration of stretch reflexes is the hallmark of spasticity. As a result, a passively stretched muscle or muscle group experiences a velocity-dependent increase in resistance. Besides the dependence on velocity, spasticity is also a length-dependent phenomenon. In the quadriceps, spasticity is more significant when the power is short than when it is long. Bending the knee, at first, an excellent resistance is met. This is probably one of the mechanisms underlying the so-called clasp knife phenomenon.
·
Spasticity affects approximately 15% to 34% of
those with stroke, ~85% of patients with Cerebral Palsy (CP), around about 40%
to 45% of TBI patients, 35% of Spinal cord compression (SCI) patients, and 35%
to 70% of patients with multiple sclerosis.
Thelansis’s “Spasticity Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022
To 2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key market
insights under the potential Spasticity treatment modalities options for eight
major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Spasticity across the 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Spasticity Market Forecast Patient-Based
Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with
sourcing, Market Event, and Product Event, Country specific Forecast Model,
Market uptake and patient share uptake, Attribute Analysis, Analog Analysis,
Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment